Stay updated on Clinical Trial of IL-2 + Nivolumab in RCC
Sign up to get notified when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.

Latest updates to the Clinical Trial of IL-2 + Nivolumab in RCC page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedLocations sections updated to include Michigan, Minnesota, and Ohio sites, replacing the prior locations blocks. Page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedSite revision label updated from v3.3.1 to v3.3.2. No changes to the study details, eligibility criteria, outcomes, or links on the page.SummaryDifference0.1%

- Check42 days agoChange DetectedFooter revision label updated from v3.2.0 to v3.3.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedNotice about government funding lapse and NIH operating status has been removed from the page.SummaryDifference0.4%

- Check64 days agoChange DetectedNo additions or deletions were detected; the page content remains focused on the study details and eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check93 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to Clinical Trial of IL-2 + Nivolumab in RCC
Enter your email address, and we'll notify you when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.